<DOC>
	<DOCNO>NCT02291029</DOCNO>
	<brief_summary>This study evaluate safety , tolerability preliminary therapeutic efficacy multiple dose intravenous infusion CFZ533 monoclonal antibody patient primary Sjögren 's syndrome ( pSS )</brief_summary>
	<brief_title>Safety , Pharmacokinetics Preliminary Efficacy Study CFZ533 Patients With Primary Sjögren 's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<criteria>Diagnosis primary Sjögren 's syndrome ESSDAI score ≥ 6 Secondary Sjögren 's syndrome Receiving cyclosphosphamide , corticosteroid bolus dose 1 mg/kg , rituximab , belimunab , immunosuppressive . At significant risk thromboembolic event Clinically significant systemic infection Significant elevate risk infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sjögren 's syndrome , CFZ533 , ESSDAI</keyword>
</DOC>